Who published this market news?

TradingView published this market news item.

Moleculin reports 37% blinded CRc in MIRACLE Part A with 74/90 enrolled

Moleculin reported preliminary blinded Part A MIRACLE results showing a 24% CR and 37% CRc (n=62) and enrollment at 74 of 90.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Jul. 31, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying impor…

Moleculin reported preliminary blinded Part A MIRACLE results showing a 24% CR and 37% CRc (n=62) and enrollment at 74 of 90.

Key Highlights:

Preliminary blinded CR 24% and CRc 37% among 62 evaluable subjects; includes control-arm subjects.
Among 30 patients with prior venetoclax, CR 23% and CRc 37%, similar to overall evaluable population.
Enrollment at 74 of 90 subjects; final Part A treatment expected in September 2026.
Comprehensive unblinded Part A results on track for Dec 2026–Feb 2027 timeframe.
No evidence of cardiotoxicity observed, differentiating Annamycin from conventional anthracyclines.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.